Journal
CANCER
Volume 121, Issue 7, Pages 997-1007Publisher
WILEY
DOI: 10.1002/cncr.28935
Keywords
glioblastoma; bevacizumab; angiogenesis; vascular endothelial growth factor; malignant glioma
Categories
Funding
- Roche
- Merck Sharp and Dohme
- Genentech
- Genentech/Roche
- EMD Serono
- Merck/Schering
- Novartis
- Amgen
Ask authors/readers for more resources
Anti-angiogenic therapy for glioblastoma has been in the spotlight for several years, as researchers and clinicians strive to find agents with meaningful efficacy against glioblastoma. Bevacizumab in particular, in the second half of the last decade, became the most significant breakthrough in anti-glioblastoma therapy since temozolomide. Optimism for bevacizumab has been somewhat challenged given recent clinical trials that have raised questions regarding its clinical effectiveness, the optimal timing of its use and the validity of endpoints, among other issues. In addition, uncertainty has recently arisen regarding the effects of bevacizumab on quality of life and neurocognitive function, two key clinical endpoints of unquestionable significance among glioblastoma patients. In this review, we highlight these controversies and other recent work related to bevacizumab for glioblastoma. Cancer 2015;121:997-1007. (c) 2014 American Cancer Society. Bevacizumab provides benefit for patients with recurrent glioblastoma. The results of recent trials have indicated that its role among newly diagnosed patients remains unclear.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available